An Open-label, Single Sequence, Crossover Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of Midazolam and S-warfarin in Patients
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Pexidartinib (Primary) ; Midazolam; Warfarin
- Indications Gastrointestinal stromal tumours; Leukaemia; Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 07 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.
- 04 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.
- 29 Sep 2017 New trial record